Beyond appetite: GLP-1 receptor drugs at the crossroads of pain, opioid reward, and overdose risk

GLP-1 receptor agonists are widely regarded as metabolic and weight-loss therapies, yet their receptors are expressed throughout central circuits governing pain, reward, and respiratory control, giving this drug class plausible neurobiological relevance that extends well beyond appetite. Three largely separate literatures have linked GLP-1 signalling to opioid-relevant outcomes, and this Perspective reads them together against the patient in whom all three meet: the person with chronic pain and opioid use disorder, two conditions that co-occur at rates well above those in the general population, in whom analgesic need, vulnerability to opioid reinforcement, and overdose risk can coexist. To that end, relevant experimental and clinical literature was identified through PubMed and Scopus, searched from database inception to 30 June 2026, supplemented by citation chaining, registry searching, and targeted hand searching, with a confirmatory search on 27 August 2026 and priority given to mechanistic studies, replicated experimental findings, and contemporary human evidence. From that synthesis three actions emerge. Spinal GLP-1 receptor agonism produces antinociception through the endogenous opioid system, recruiting β-endorphin release with downstream μ-opioid receptor activation. In animals, these agents reduce opioid taking, seeking, and reinstatement, with mesolimbic dopamine signalling the likely route. And in large observational cohorts, including three target-trial emulations, patients prescribed them show lower rates of opioid overdose and of incident opioid use disorder. The evidence behind the three is not of one kind: a defined spinal mechanism untested in humans, a reproducible animal behaviour now entering human trials, and a large human association, not uniform across comparators, whose mechanism is unknown. These actions meet in one patient without constituting three confirmations of one process: the convergence is clinical rather than mechanistic. That distinction is the argument of this Perspective, and it defines what would have to be shown before these observations could inform practice.